Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study
Gupta, V.K.; Dhar, A.; Srinivasan, S.; Rattan, A.; Sharma, M.P.
American Journal of Gastroenterology 92(7): 1140-1142
1997
ISSN/ISBN: 0002-9270 PMID: 9219786 Document Number: 477723
Objectives: Lansoprazole, a newer benzimidazole, is more potent than omeprazole in its anti-Helicobacter pylori effect in vitro. The present study was aimed at assessing its efficacy in a developing country. Methods: Fifty patients were randomized to receive either lansoprazole or omeprazole, with norfloxacin for 2 wk; the ulcer healing rates, H. pylori eradication rates, and recurrence rates were compared over a 6-month period. Results: Both lansoprazole and omeprazole were equally effective in inducing healing of ulcer (96.1 vs 95.5%, p gt 0.05) and eradicating H. pylori (76.9 vs 63.9%, p gt 0.05), with very low recurrence rates over a 6-month follow-up period. Conclusions: Either lansoprazole or omeprazole combined with norfloxacin is effective in eradicating H. pylori in a high percentage of cases of duodenal ulcer, with little difference between the two proton pump inhibitors.